ReviewEuropean urology open science2026
PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.
Review in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Although prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is commonly used for both initial staging and restaging at biochemical recurrence for patients diagnosed with prostate cancer (PCa), its role in the evaluation of treatment response is currently not validated. Objectives: We aimed to identify studies that implemented PSMA PET/CT as a restaging modality for patients with hormone-sensitive PCa (HSPC) and highlight the evolution of PSMA PET/CT parameters to assess its potential use for treatment response evaluation. Evidence Acquisition: A systematic review was performed using the MEDLINE, Scopus, and Embase databases until December 2025. Studies deemed eligible were those reporting PSMA expression dynamics under either systemic therapy or after radiotherapy (RT). Evidence synthesis: A total of 11 studies were included, including two prospective single-arm studies and nine retrospective studies. Under androgen deprivation therapy (ADT), a decrease in PSMA expression was observed across all disease sites. In one prospective study, a flare phenomenon (increase ≥20% in tracer uptake) was observed at the lesion level in 26% of bone lesions and 11% of nodal and prostate lesions at 3-4 wk, with a median change in maximum standardized uptake value (ΔSUVmax) of +50% (interquartile range 32-72) in bone lesions showing flare. At 22 wk, one retrospective study reported mean SUVmax reductions of 48%, 59%, and 74% in prostate, nodal, and bone lesions, respectively. Other studies at different time points each reported reductions in prostate SUVmax ranging from 49% to 67%, with differences in whether estimates were summarized as means or medians. After RT, one retrospective study suggested that the reduction in prostate SUVmax may be more pronounced in patients receiving concomitant ADT (mean reduction -59% ± 25% vs -45% ± 31% for RT alone; Conclusions: PSMA PET-derived parameters hold the potential to personalize treatment strategies depending on treatment response. The relationship between changes in PSMA expression and oncological outcomes warrants further investigation in other studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.